Zhejiang University: Neoplasms trials

The registry lists 16 Neoplasms studies with Zhejiang University as lead sponsor. 11 are open to participants now and 0 have results posted.

Early Phase 1 2Phase 1 8Phase 2 3No phase 5(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• IL-5 CAR-T Cell Therapy for Refractory/Relapsed Eosinophilic LeukemiaRecruitingNCT07257640Phase 1
• Anti-Mesothelin CAR-T Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid TumorsRecruitingNCT07010523Not applicable
• MT027 in Patients With Advanced Peritoneal Malignancies or Abdominal Metastatic Solid TumorsRecruitingNCT06912152Phase 1
• Clinical Application of 99mTc-FDPH46 SPECT/CT Imaging in Malignant Solid Tumor: a Prospective Exploratory StudyNot yet recruitingNCT06753513
• A Clinical Study of Anti-CD70 UCAR-T in Relapsed or Refractory Solid TumorsNot yet recruitingNCT06383507Phase 1
• Universal Dual-target NKG2D-NKp44 CAR-T Cells in Advanced Solid TumorsRecruitingNCT05976906Phase 1
• UCLM802 (Anti-Mesothelin CAR-T) Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid TumorsRecruitingNCT05848999Phase 1
• CD7 CAR-T Bridging to alloHSCT for R/R CD7+Malignant Hematologic DiseasesRecruitingNCT05827835Phase 1/2
• Exploring Biomarkers of the Carcinogenesis of Intraductal Papillary Mucinous Neoplasm (IPMN) of the PancreasRecruitingNCT05433935
• Clinical Study on the Safety and Effectiveness of NK Cells/Combined Monoclonal Antibodies in the Treatment of Hematological MalignanciesNot yet recruitingNCT04662788Early Phase 1
• LMP1 CAR-T for Patients With LMP1 Positive Infectious Diseases and Hematological MalignanciesNot yet recruitingNCT04657965Early Phase 1
• T Cell Receptor Gene-Engineered and Dominant Negative TGF-β Receptor T Cell Therapy Targeting KRAS Mutations in the Treatment of Subjects With Advanced Solid TumorActive, not recruitingNCT07474168Phase 1
• Sequential Radiotherapy With CAR-T Cells in the Treatment of Relapsed and Refractory Hematological Malignancies With Extramedullary LesionsStatus unknownNCT04790747Phase 1/2
• CAR-T Cellular Therapy for B Cell Malignancies Involved in CNSStatus unknownNCT04287309
• Anlotinib Hydrochloride Capsules Combined With CAPEOX in RAS and BRAF Wild-type mCRC PatientsCompletedNCT04080843Phase 2
• Surgery With HIPEC in Treating Patients With a High Risk of Developing Colorectal Peritoneal CarcinomatosisCompletedNCT02179489Not applicable